---
title: "Aureka’s $100M Series B: Lab-in-the-Loop Biological Foundation Models"
description: "Granite Asia backed Aureka Biotechnologies’ $100M Series B (~$200M cumulative) to scale AuraIDE — closed-loop AI + wet lab for antibody discovery."
date: 2026-08-10T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "biotech-life-sciences", "artificial-intelligence", "healthtech"]
source: https://venturecapitaltracker.com/2026-aureka-biotechnologies-100m-series-b-bio-foundation-models
---

# Aureka’s $100M Series B: Lab-in-the-Loop Biological Foundation Models

> Granite Asia backed Aureka Biotechnologies’ $100M Series B (~$200M cumulative) to scale AuraIDE — closed-loop AI + wet lab for antibody discovery.

**Aureka Biotechnologies** closed a **$100 million Series B** on **August 10, 2026**, with **Granite Asia** taking the first tranche exclusively and a strategic investor leading a later tranche. **HighLight Capital**, **MPCi**, and **NRL Capital** participated. Cumulative funding is nearly **$200 million**. The company is building biological foundation models that learn from a **wet-lab loop**, not only public protein databases.

## Key facts

| Field | Detail |
| --- | --- |
| Company | Aureka Biotechnologies (Laguna Hills, CA & Shanghai) |
| Round | $100M Series B |
| Date | August 10, 2026 |
| Key capital | Granite Asia (first tranche); strategic lead (later); HLC, MPCi, NRL |
| Cumulative | ~$200M |
| Product | AuraIDE foundation model; OpenDDE open-source; Lab-in-the-Loop infra |
| Commercial | Pharma partnerships; tens of millions revenue over ~2 years (company) |
| Founded | 2023 (CEO Dr. Weian Zhao) |
| Use of proceeds | Next-gen model training + Lab-in-the-Loop upgrades |

## Who uses the product — and for what job

**Users:** large pharma discovery teams and Aureka’s own pipeline groups chasing hard antibody problems (GPCRs, dual-target designs).

**Job:** generate and validate developable molecules faster by closing the loop between **model proposals → high-throughput experiments → post-training**, instead of treating the lab as a late QA step.

OpenDDE (open-source AuraIDE cousin) is the credibility play for third-party structure/design benchmarks — useful when buyers distrust closed black boxes.

## Why now

- Structure prediction alone is table stakes; buyers want **functional, developable assets**.
- Static public datasets plateau; proprietary **functional screening data** becomes the moat.
- Chai Discovery and peers reset TechBio valuations — capital is concentrating on teams with **lab + model** flywheels.
- Cross-border antibody markets still need partners who can run dual US/China R&D footprints carefully.

## Why Granite Asia — portfolio fit

Granite Asia (~$10B AUM platform per its own materials in the release) financing the first tranche exclusively is a classic **region-fluent lead** for a dual-HQ TechBio: underwrite science risk and global partner intros without forcing an early US mega-fund board reset.

**Likely founder rationale:** keep Asia-native capital that already believes in closed-loop AI-for-science, add a strategic for distribution into pharma pipelines, and use Series B to train larger models — not to “pivot to SaaS.”

We do **not** currently list Granite Asia / HLC / MPCi / NRL as `/fund/` pages.

## Competitive map

| Player | Lane |
| --- | --- |
| Chai Discovery / structure-first AI bio | Adjacent foundation-model TechBio |
| Classic CRO + ML bolt-ons | Experiment capacity without owned foundation models |
| Big pharma internal AI groups | Build vs buy tension; often partner externally |
| Pure computational design shops | Weak without wet-lab feedback ownership |

## When not to underwrite this

- Wrong if “biological world model” language is treated as a shipped product — it is a roadmap phrase.
- Wrong if tens of millions revenue is extrapolated to SaaS multiples.
- Wrong if open-source OpenDDE rankings are confused with proprietary AuraIDE clinical success.

## Practical takeaway

- **Founders (TechBio):** Show the **data flywheel** (what experiments feed which training loop) before the world-model slogan.
- **Investors:** Diligence partner concentration and IP/geography constraints as hard as FoldBench scores.
- **Operators / scouts:** Compare Aureka to other closed-loop antibody platforms on **time-to-developable candidate**, not blog benchmarks alone.

### Sources

1. PR Newswire (Aug 10, 2026): https://www.prnewswire.com/news-releases/aureka-biotechnologies-raises-us100-million-series-b-to-build-a-biological-world-model-for-drug-discovery-302847165.html
2. Related: [/startup/aureka-biotechnologies](/startup/aureka-biotechnologies) · [/2026-chai-discovery-400m-series-c-index-sequoia](/2026-chai-discovery-400m-series-c-index-sequoia)